Open Access

BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells

  • Authors:
    • Li Meng
    • Xiaoyi Wang
    • Weihua Liao
    • Jianling Liu
    • Yiwei Liao
    • Qiongqiong He
  • View Affiliations

  • Published online on: October 10, 2017     https://doi.org/10.3892/or.2017.6019
  • Pages: 3327-3334
  • Copyright: © Meng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Increasing evidence indicates that BAF53a is crucial for embryonic development and maintenance of stemness, and may be associated with epithelial-mesenchymal transition (EMT), which suggests its involvement in cancer progression. However, the role of BAF53a in glioma remains unknown. In the present study, BAF53a was found to be highly expressed in glioma tissues and was associated with poor overall survival (OS) and progression-free survival (PFS) in glioma patients. A multivariate Cox regression analysis revealed that BAF53a might be an independent prognostic factor for OS and PFS in glioma patients. Further functional analysis indicated that BAF53a overexpression could promote proliferation and increase the motility and invasion of U87 glioma cells, whereas BAF53a knockdown had the opposite effect. In addition, BAF53a expression was associated with the levels of E‑cadherin and vimentin expression in glioma tissues. This was further confirmed in U87 cells expressing different levels of BAF53a; BAF53a overexpression was concomitant with decreased E‑cadherin and increased vimentin expression, whereas BAF53a knockdown showed the opposite pattern of expression. Taken together, these results suggest that BAF53a may be a novel prognostic factor for glioma patients, and that BAF53 may facilitate glioma progression by promoting proliferation, invasion, and associate with EMT. Therefore, BAF53a could be a potential promising biomarker and a target for the treatment of glioma.
View Figures
View References

Related Articles

Journal Cover

December-2017
Volume 38 Issue 6

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Meng L, Wang X, Liao W, Liu J, Liao Y and He Q: BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. Oncol Rep 38: 3327-3334, 2017.
APA
Meng, L., Wang, X., Liao, W., Liu, J., Liao, Y., & He, Q. (2017). BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells. Oncology Reports, 38, 3327-3334. https://doi.org/10.3892/or.2017.6019
MLA
Meng, L., Wang, X., Liao, W., Liu, J., Liao, Y., He, Q."BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells". Oncology Reports 38.6 (2017): 3327-3334.
Chicago
Meng, L., Wang, X., Liao, W., Liu, J., Liao, Y., He, Q."BAF53a is a potential prognostic biomarker and promotes invasion and epithelial-mesenchymal transition of glioma cells". Oncology Reports 38, no. 6 (2017): 3327-3334. https://doi.org/10.3892/or.2017.6019